SBIR/STTR Research Award

Fast Biomimetic Phospholipid Assay for Modeling Brain Perfusion Kinetics of Drugs

Award identifier 44c17878c11518f1798763a36b15d50ab34039ce0996207da589969d3273c1f9Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$97,470

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PION, INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
HJKUB4P6MRK6
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): We propose the development of a high-throughput analytic tool that can accurately assess passive permeability of drug-like molecules across the blood-brain barrier (BBB), using an artificial membrane measuring technique developed by plON. The parallel artificial membrane permeability assay (PAMPA) will incorporate a new, specially-designed permeability model based on the use of biomimetic membranes. The method will be suitable for screening large libraries of molecules, at about 1000 times lower cost than in vivo rodent-model measurements. The new PAMPA BBB barrier lipid will be optimized in composition, initially mimicking the lipid composition of endothelial cells, but "trained" to closely match available in situ brain perfusion data, derived from the "knockout" mouse (mdr1a(-/-)) model. To model the near zero thickness aqueous boundary layer environment in the brain microcapillaries, stirring will need to be performed on both sides of the membrane barrier in a specially-designed (plON) 96-well microtitre plate. We will use 39 identified drug molecules, whose highly-reliable knockout mouse in situ brain perfusion data are already available, as the training set for the new BBB-PAMPA model. With these, our aim in the new model is to reach the PAMPA vs. in situ linear-regression correlation coefficient, r2 > 0.9, without the use of in silico "booster" descriptors. However, as a backup, we will embrace the concept of in silicoenhanced measured data modeling, and will use this strategy as needed. The proposed high-throughput PAMPA BBB permeability technique is important to public health because it will allow large scale, low-cost compound screening producing data with enhanced downstream value earlier in discovery programs, thus eliminating molecules with questionable drugability characteristics sooner and help lower the current, estimated 98% attrition rate. This will contribute to the timely development of better medicines at lower cost.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

2 SBIR/STTR records share this UEI (2005–2007). Reported award amounts total $539,811. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.